Literature DB >> 11473208

Long-term effects of 'ecstasy' abuse on the human brain studied by FDG PET.

R Buchert1, J Obrocki, R Thomasius, O Väterlein, K Petersen, L Jenicke, K H Bohuslavizki, M Clausen.   

Abstract

The popular recreational drug, 'ecstasy', mainly contains 3,4-methylenedioxymethamphetamine (MDMA) as the psychotropic agent. MDMA is suspected of causing neurotoxic lesions to the serotonergic system as demonstrated by animal studies, examinations of human cerebrospinal fluid, and the first positron emission tomography (PET) studies using the serotonin transporter ligand [11C]-McN5652. Damage of serotonergic afferents might mediate long-lasting alterations of cerebral glucose metabolism as a secondary effect. To study a relationship between ecstasy use and long-lasting alterations, PET using 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) was performed in 93 ecstasy users and 27 subjects without any known history of illicit-drug abuse. As an index of glucose metabolism, mean normalized FDG uptake was determined in both groups using a computerized brain atlas, and was compared for a selected number of brain regions. FDG uptake was normalized in each individual by dividing local FDG uptake by the maximum FDG uptake in the individual's brain. Within the group of ecstasy users we examined the relationship between FDG uptake and cumulative ecstasy dose, time since last ecstasy ingestion at the time of PET scanning, and age at first ecstasy use, respectively. Normalized FDG uptake was reduced within the striatum and amygdala of ecstasy users when compared to controls. No statistically significant correlation of the FDG uptake and the cumulative dose of ecstasy was detected. A positive correlation was found in the cingulate between FDG uptake and the time since last ecstasy ingestion. As compared to the control group, normalized FDG uptake in the cingulate was reduced in ecstasy users who took ecstasy during the last 6 months, while it was elevated in former ecstasy users who did not consume ecstasy for more than 1 year. FDG uptake was significantly more affected in ecstasy users who started to consume ecstasy before the age of 18 years. In conclusion, ecstasy abuse causes long-lasting effects on glucose metabolism in the human brain. These effects are more severe in the case of very early abuse. However, several questions still remain to be answered, i.e. the correlation of the neuronal alterations and the history of ecstasy use (cumulative dose, and time since the last dose) and its reversibility.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11473208     DOI: 10.1097/00006231-200108000-00007

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  18 in total

1.  Effects of exposure to amphetamine derivatives on passive avoidance performance and the central levels of monoamines and their metabolites in mice: correlations between behavior and neurochemistry.

Authors:  Kevin Sean Murnane; Shane Alan Perrine; Brendan James Finton; Matthew Peter Galloway; Leonard Lee Howell; William Edward Fantegrossi
Journal:  Psychopharmacology (Berl)       Date:  2011-10-13       Impact factor: 4.530

2.  Correlates of African American female adolescent offenders 3, 4-Methylenedioxymethamphetamine (MDMA or "Ecstasy") use and sexually transmitted infection morbidity.

Authors:  Torrance Stephens; Rhonda Conerly Holliday; Shakita Hopkins; Shanhol Rose; Ronald Braithwaite; Selina Smith
Journal:  J Hum Behav Soc Environ       Date:  2015-09-29

3.  "Ecstasy"-induced neurotoxicity: the contribution of functional brain imaging.

Authors:  M Schreckenberger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02       Impact factor: 9.236

Review 4.  Altered energy production, lowered antioxidant potential, and inflammatory processes mediate CNS damage associated with abuse of the psychostimulants MDMA and methamphetamine.

Authors:  Luke A Downey; Jennifer M Loftis
Journal:  Eur J Pharmacol       Date:  2014-01-28       Impact factor: 4.432

5.  Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users.

Authors:  Ralph Buchert; Rainer Thomasius; Kay Petersen; Florian Wilke; Jost Obrocki; Bruno Nebeling; Lutz Wartberg; Pavlina Zapletalova; Malte Clausen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-17       Impact factor: 9.236

Review 6.  Brain: normal variations and benign findings in fluorodeoxyglucose-PET/computed tomography imaging.

Authors:  Valentina Berti; Lisa Mosconi; Alberto Pupi
Journal:  PET Clin       Date:  2014-04

Review 7.  Neuropathology of substance use disorders.

Authors:  Jean Lud Cadet; Veronica Bisagno; Christopher Mark Milroy
Journal:  Acta Neuropathol       Date:  2013-11-29       Impact factor: 17.088

8.  Factors associated with initiation of ecstasy use among US adolescents: findings from a national survey.

Authors:  Ping Wu; Xinhua Liu; Bin Fan
Journal:  Drug Alcohol Depend       Date:  2009-09-24       Impact factor: 4.492

9.  Self-reported ecstasy (MDMA) use and past occurrence of sexually transmitted infections (STIs) in a cohort juvenile detainees in the USA.

Authors:  Torrance Stephens; Rhonda Conerly Holliday; Jerriyauna Jarboe
Journal:  J Community Health       Date:  2015-04

Review 10.  Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms.

Authors:  Jean Lud Cadet; Irina N Krasnova; Subramaniam Jayanthi; Johnalyn Lyles
Journal:  Neurotox Res       Date:  2007-04       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.